A study of the once-weekly investigational dipeptidyl peptidase-4 omarigliptin reported a clinically meaningful reduction in glycated hemoglobin that was maintained throughout the study.
Higher magnesium intake was linked to a 15% lower risk for type 2 diabetes.
Overall reduction in HbA1c was higher in people with T2D vs those with T1D.
New monitoring system involves the placement of a small sensor wire beneath the skin surface to continuously monitor glucose levels.
Researchers examined the efficacy of lifestyle intervention on glycemic control in type 2 diabetes.
GlaxoSmithKline expects Tanzeum supplies to be depleted by July 2018.
Approval for the new indication follows a review of the results of the LEADER trial.
Sodium-glucose cotransporter 2 inhibitors reduced both systolic and diastolic blood pressure in patients with type 2 diabetes.
One hundred fifteen patients used the FreeStyle Libre Pro sensor to monitor interstitial fluid glucose for 14 days.
A randomized double-blind trial examined the safety and efficacy of ertugliflozin plus metformin for inadequately controlled type 2 diabetes.
Canagliflozin reduced levels of cardiovascular stress biomarkers N-terminal pro-B type natriuretic peptide and high sensitivity troponin I.
Patients with type 2 diabetes had lower rates of heart failure hospitalization, MACE, and all-cause mortality when treated with dapagliflozin.
No between-group differences for factors such as glycemic control, endogenous glucose production, and insulin sensitivity were found.
Results of 2 large clinical trials confirmed previous safety concerns surrounding canagliflozin therapy for type 2 diabetes.
The combined treatment regimen of metformin and liraglutide led to complete remission in 74% of patients with new onset type 2 diabetes.
Early initiation of insulin therapy in patients with type 2 diabetes improved HbA1c, fasting blood sugar, postprandial blood sugar, and BMI.
Researchers examined 24-hour and ambulatory blood pressure to determine the relationship between hypertension and low levels of vitamin D.
A comprehensive systematic review analyzes whether specific sodium-glucose cotransporter 2 inhibitors were more likely to be associated with adverse renal events in patients with type 2 diabetes.
A cohort study of primary care records in the United Kingdom did not find an increased risk of major cardiovascular events in patients with type 2 diabetes treated with insulin.
Researchers found that those at risk for low vitamin B12 levels are often not properly monitored.
Endocrinology Advisor Articles
- Two Phases of C-Peptide Decline Identified in Type I Diabetes
- Dulaglutide Effective for Patients With T2D, Moderate to Severe CKD
- Incidence of Diabetes Influenced by Endocrine-Disrupting Chemicals in the Environment
- Guidelines for Management of Hypothalamic-Pituitary, Growth Disorders in Childhood Cancer Survivors
- Assessment of Low-Dose Aspirin As Chemoprevention in Type 2 Diabetes
- Using Latent Class Trajectory Analysis to Determine Glucose Response Curve Patterns
- First CGM System With Implantable Glucose Sensor Approved
- Adjunctive Metformin for Insulin Resistance in T1D: A Clinical Perspective
- Risk for Below Knee Amputations With Canagliflozin vs Other Antihyperglycemic Agents
- Empagliflozin, Linagliptin Combination Therapy vs Linagliptin Monotherapy for Type 2 Diabetes
- Government and Industry Lead the Way in Funding USPSTF Systematic Reviews
- New Romosozumab BLA Includes Data from Additional Osteoporosis Trials
- Impact of Maternal Diabetes on Outcomes in Very Preterm, Very Low-Birth-Weight Infants
- Age-Related Differences in Manifestation of Cushing Disease Identified
- International Group Develops Best Practices for Drug Packaging